High-dose liraglutide improves metabolic syndrome in poor responders to bariatric surgery

Frontiers in Nutrition

Nutrition

Alfredo Pulvirenti¹  Federica Vinciguerra²  Claudia Degano²  Lucia Frittitta³  Roberto Baratta⁴  Carla Di Stefano⁵  Luigi Piazza⁵ 

[1] Bioinformatics Unit, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy;Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy;Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy;Diabetes and Obesity Center, Garibaldi Hospital, Catania, Italy;Endocrinology Unit, Garibaldi Hospital, Catania, Italy;General and Emergency Surgery Department, Garibaldi Hospital, Catania, Italy;

关键词: obesity;    bariatric surgery;    metabolic syndrome;    liraglutide;    weight loss;   

DOI  :  10.3389/fnut.2023.1183899

 received in 2023-03-16, accepted in 2023-08-24,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundBariatric surgery (BS) represents the most effective therapy for obesity class III, or class II with at least one weight-related comorbidity. However, some patients have insufficient weight loss or clinically relevant weight regain after a successful primary procedure. This study aimed to assess the efficacy of liraglutide treatment on weight loss, body composition and improvement of metabolic syndrome (MS) in patients defined as poor responders after BS.MethodsThe study involved 59 non-diabetic adults with obesity (M/F: 17/42, age: 38.6 ± 11.8 years, BMI 38.3 ± 5.5 kg/m2) who had been treated with BS and experienced a poor response, categorized as either IWL (insufficient weight loss) or WR (weight regain). All patients were prescribed pharmacological therapy with liraglutide and attended nutritional counseling. Anthropometric and clinical measurements, body composition and the presence of MS defined according to the ATP-III classification were evaluated before starting liraglutide and after 24 weeks of treatment.ResultsAfter 24 weeks of treatment with liraglutide, the mean weight loss was 8.4% ± 3.6% with no difference between gender, bariatric procedure, or type of poor response (IWL or WR). A significant decrease in fat mass, free-fat mass and total body water was documented. After 24 weeks, patients presented significantly lowered fasting glucose, total cholesterol, triglycerides, AST and ALT. The prevalence of MS was reduced from 35% at baseline to 1.6% after 24 weeks. No patients discontinued the treatment during the study.ConclusionIn patients who experience poor response after BS, liraglutide is well tolerated and promotes significant weight loss, ameliorates cardiometabolic comorbidities, and reduces the prevalence of MS.

【 授权许可】

Unknown   
Copyright © 2023 Vinciguerra, Piazza, Di Stefano, Degano, Pulvirenti, Baratta and Frittitta.

【 图 表 】

fnagi-15-1217746-i031.jpg

fnut-10-1183899-i002.tif

fmicb-14-1258415-i038.tif